Latest News

Dr. Charlie Serhan, awarded the 2016 Ross Prize in Molecular Medicine

It gives me great pleasure to announce that Charles N. Serhan, PhD, is the recipient of the 2016 Ross Prize in Molecular Medicine. Dr. Serhan, of Brigham and Women's Hospital and Harvard Medical School, receives this award in recognition of his important discovery concerning the mechanistic basis for inflammation resolution and translation of that discovery to the clinic.

The annual Ross Prize in Molecular Medicine is issued via the Feinstein Institute's peer-reviewed, open-access journal, Molecular Medicine, and is awarded annually to scientists who have made a demonstrable impact in the understanding of human diseases pathogenesis and/or treatment, and who hold significant promise for making even greater contributions to the general field of molecular medicine.

Dr. Serhan will receive an award trophy and honorarium of $50,000 from Molecular Medicine, and present the keynote lecture at the Award Ceremony and Mini-Symposium on Monday, June 13, 2016, at the New York Academy of Sciences in Manhattan. To read more about the Ross Prize in Molecular Medicine, click here.

Dr. Serhan has received numerous distinguished lectureships and awards including the John Vane Lecture and William Harvey Outstanding Scientist Medal in 2008. He has published over 500 publications and 400 patents, and served as a mentor to over 40 trainees throughout his career.

On behalf of the Committee of the Ross Prize in Molecular Medicine and the Feinstein Institute, please join me in congratulating Dr. Serhan.


Christopher J. Czura, PhD Publisher Feinstein Institute Press Molecular Medicine & Bioelectronic Medicine

Charles Serhan received the International Union of Biochemistry and Molecular Biology Medal

Charles Serhan received the International Union of Biochemistry and Molecular Biology Medal on January 24, 2016. He presented the Award Lecture titled, “Structural Elucidation of Novel Mediators in Resolution of Inflammation, Infection and Tissue Regeneration” at the 49th Annual Miami Winter Symposium on Inflammation. Serhan was honored for identifying novel pathways and cellular targets critical in regulating neutrophil-mediated inflammation and establishing the templates for physiologic small molecule-based interventions.r

Shernan Elected President of the National Board of Echocardiagraphy

Stanton K. Shernan, MD, FAHA, FASE, director of Cardiac Anesthesia in BWH's Department of Anesthesiology, Perioperative and Pain Medicine, has been elected president of the National Board of Echocardiography (NBE). Shernan has preformed 15 years of service with the NBE and was selected for his international reputation and devotion of his academic career to research and education in the use of perioperative, echocardiography and its influence on surgical decision-making.

Since its inception, the NBE has become the leading, international renowned board for physicians seeking certification in transthoracic and transesophageal echocardiography. Its mission is to develop a certification process that will publicly recognize those physicians who have completed an approved training program in echocardiography, and passed an examination of special competence in echocardiography that is developed and administered by the NBE.

Farokhzad Awarded Nanotechnology Prize

Omid Farokhzad, MD, director of the Laboratory of Nanomedicine and Biomaterials at BWH and associate professor in the Department of Anesthesiology, was recently named one of two 2013 Laureates of the RUSNANOPRIZE, the largest international nanotechnology prize, for his work in advancing nanoparticle technologies. Farokhzad is being recognized in the field of Nanomaterials and Surface Modification for his role in the innovation, development and industrialization of nanoparticle technologies for medical applications.

The award is also given to a company that has achieved significant commercial success due to implementation of the winning research. Given this, the RUSNANOPRIZE also recognizes BIND Therapeutics, cofounded by Farokhzad, for successfully applying his winning research into industrial production. BIND's lead drug candidate is BIND-014, which is a targeted and controlled release nanoparticle in phase II clinical trials for treatment of lung and prostate cancers. BIND-014 is the first targeted and controlled release nanoparticle technology to reach human clinical trial.

Read more at this BWH page.

Muehlschlegel Receives NHLBI R01 Grant

Jochen “Danny” Muehlschlegel, MD, MMSc, director of Cardiovascular Anesthesia Research at BWH, was awarded a R01 grant from The National Heart, Lung, and Blood Institute (NHLBI) for his research on genetics of gene expression. This $1.25 million grant will span a five-year period.

Muehlschlegel's project will look at the genetic factors of ischemic heart disease, a highly heritable disorder, and the leading cause of mortality worldwide. The goal is to develop insights that may facilitate the development of new therapeutic strategies to alleviate the burden of myocardial injury in humans.

The NHLBI provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.

Farokhzad named a Boston Business Journal 2013 Champion in Healthcare

Three individuals and one division at BWH were named 2013 Champions in Healthcare by the Boston Business Journal, an annual award that honors the leading professionals in Massachusetts’ stellar healthcare industry. The awards will be announced Aug. 16 in the print edition of the BBJ.

Omid Farokhzad, MD, director of the Laboratory of Nanomedicine and Biomaterials, won in the “innovator” category for helping define the health care field with pioneering research or a new procedure.

Over the past decade, Farokhzad has iteratively developed targeted nanoparticles with the potential to treat a wide range of conditions, from solid tumors to cardiovascular conditions. Farokhzad has authored approximately 95 publications and is an inventor of more than 125 US and International patents/patent applications that have formed the foundation for three biotechnology companies.

Potential treatment for severe influenza found in Omega-3 fatty acids

In a study published March 7, 2013 in Cell, a modified omega-3 fatty acid known as protectin D1 was found to markedly increase the chances of survival in mice with infected with various strains of influenza, including the H1N1 strain behind the 2009 ‘swine flu’ epidemic.

“The authors show for the first time that [protectin D1] actually disrupts replication of influenza,” says Charles Serhan, an anesthesiologist at Brigham and Women’s Hospital in Boston. “It provides a natural template for new therapeutic development.”

ajax loader